Pneumococcal 20-valent Conjugate Vaccine

Streptococcus pneumoniae is a bacterial pathogen transmitted via respiratory droplets, close contact, or direct exposure to respiratory secretions. With over 90 known serotypes, different strains vary in community prevalence, invasiveness, and antibiotic resistance. Pneumococcal infections fall into two categories: non-invasive conditions and Invasive Pneumococcal Disease (IPD), which carries significantly higher clinical risks. Early vaccination is widely recognized as the most effective strategy to prevent IPD and its complications.

Clinical presentation depends on the primary site of infection. High-risk groups (elderly individuals, young children, and immunocompromised patients) or individuals experiencing severe symptoms should seek immediate medical attention:

Pneumonia (Lung Infection): Fever, chills, productive cough, shortness of breath, chest discomfort, fatigue, and loss of appetite.

Meningitis (Emergency Condition): High fever, severe headache, neck stiffness, confusion, and lethargy.

Otitis Media (Common in Children): Ear pain, fever, fluid drainage, and potential long-term hearing impairment from recurrent infections.

PCV20 is an inactivated conjugate vaccine designed to provide targeted immunological protection against 20 distinct Streptococcus pneumoniae serotypes.

PCV20 reduces the risk of vaccine-serotype pneumococcal diseases, including pneumonia, bacteremia, and meningitis (Invasive Pneumococcal Disease).

Individuals aged 2 and older (including adults and seniors) require only a single-dose administration.

Postponement: Individuals presenting with acute fever or severe systemic illness should defer vaccination until recovery.

Contraindications: Individuals with a history of severe allergic reactions to any vaccine component require medical evaluation prior to administration.

Post-Vaccination Observation: Recipients are advised to remain on-site for at least 15 minutes post-injection to manage any rare immediate hypersensitivity reactions.

Common Local Reactions: Mild pain, redness, or swelling at the injection site, typically resolving within 2 days.

Systemic Reactions: Mild fever, fatigue, headache, chills, or myalgia (muscle pain).

When to Seek Immediate Care: If severe hypersensitivity symptoms occur (e.g., dyspnea, swelling of the lips or tongue, urticaria/hives) or if high fever persists, consult a physician immediately.

Adults who have previously received a single dose of PCV13 or 23-valent pneumococcal polysaccharide vaccine (23vPPV) may consider receiving PCV20 after a 1-year interval to extend protection across additional serotypes. Consult a doctor for personalized booster schedules.

No. Individuals who receive PCV20 do not require additional doses of 23vPPV.

The Centre for Health Protection (CHP) in Hong Kong recommends priority PCV20 vaccination for:

Adults aged 50 or above

Individuals with chronic health conditions (e.g., chronic lung disease, cardiovascular disease, diabetes)

Smokers

Immunocompromised individuals (e.g., those undergoing immunosuppressive therapy or long-term medication regimens)

Children aged 2 and older with high-risk health factors